

# Updates To Carelon Medical Benefits Management Inc. Genetic Testing Clinical Appropriateness Guidelines

**Effective for dates of service on and after November 5, 2023**, the updates listed below will apply to the Carelon\* Clinical Appropriateness Guidelines. As part of the Carelon guideline annual review process, these updates advance efforts to drive clinically appropriate, safe and affordable healthcare services.

## **Carrier Screening in the Prenatal Setting and Preimplantation Genetic Testing**

- Expanded targeted screening to third-degree relatives
- Excluded whole exome and whole genome assays for the purposes of carrier screening

## **Cell-free DNA Testing (Liquid Biopsy) for the Management of Cancer**

- Expanded ESR1 ctDNA testing

## **Hereditary Cancer Testing**

- BRCA1 and BRCA2 testing – raised risk profile for first-degree relatives with breast cancer diagnosed age cut-off to 50 years and younger

## **Somatic Tumor Testing**

- Tumor-agnostic testing for patients with advanced solid tumors – expanded RET fusion testing
- Metastatic breast cancer – expanded testing for somatic pathogenic variants of ESR1
- Chronic myeloid leukemia (CML) – expanded specimen type to include peripheral blood

For questions about guidelines, email Carelon at [medicalbenefitsmanagement.guidelines@carelon.com](mailto:medicalbenefitsmanagement.guidelines@carelon.com). Additionally, you may access a copy of the [current and upcoming guidelines](#).

\*On March 1, 2023, AIM Specialty Health began operating as Carelon Medical Benefits Management, Inc.

*Carelon Medical Benefits Management, an independent company, is contracted to provide precertification services for Blue Cross and Blue Shield of Alabama.*